IMRELIX
LIVE

Serial Number

79209728

Owner

Immune System Regulation Holding AB

Filing Date

Mar 23, 2017

Add to watchlist:

No watchlists yet
View on USPTO

IMRELIX Trademark

Serial Number: 79209728 • Registration: 5450609

IMRELIX is a trademark filed by Immune System Regulation Holding AB on March 23, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Immune System Regulation Holding AB (2 trademarks)

Rörstrandsgatan 58

Entity Type: 03

ISR Immune System Regulation Holding AB (3 trademarks)

Rörstrandsgatan 58

Entity Type: 03

Trademark Details

Filing Date

March 23, 2017

Registration Date

April 24, 2018

Published for Opposition

February 6, 2018

Cancellation Date

November 8, 2024

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment and prevention of viral and infectious diseases and pharmaceutical preparations for the treatment of immune dysfunction and pharmaceutical preparations for the treatment of human immunodeficiency virus

Scientific research within the medical, pharmaceutical and bacteriological area, namely, Synthetic chemistry and generation of new chemical entities based on molecular structures of macrolides and of GnRH molecules to identify specific lead drug candidates for infectious diseases. Toxicology studies and preparation of investigational new drugs (INDs) according to good laboratory practice (GLP) standard operating procedures, analysis of pharmacokinetics and metabolism of drugs and new chemical entities, preparation of pharmaceutical formulations, high-throughput screening of new chemical entities in the field of anti-viral therapeutics, and consultancy and information relating thereto, conducting of tests regarding medical applications; packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, design and development of granulation technology and tablet technology namely, selection of lead drug candidates in the field of anti-viral therapeutics based on specific molecular structures, design of pharmaceutical and medical preparations through analysis of pharmacokinetics and metbolism of drugs and new chemical entities, manufacturing of pharmaceutical formulations according to good manufacturing practice (GMP) standard operating procedures, and consultancy and information relating thereto

Information and advice relating to pharmaceutical preparations, diseases and medical conditions and treatment, namely, information and advice on-line via computer networks or the Internet and providing information relating to prevention, diagnosis and treatment of infectious diseases and information and advice relating to diagnosis and treatment of diseases and medical disorders

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Feb 19, 2026 INNT
GENERIC MADRID TRANSACTION SENT TO IB
Dec 30, 2025 XXSS
GENERIC MADRID TRANSACTION CREATED
Dec 30, 2025 XXCR
NEW REPRESENTATIVE AT IB RECEIVED
Nov 21, 2025 NREP
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 8, 2025 INTR
CANCELLED SECTION 71
Nov 8, 2024 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Feb 18, 2022 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Oct 28, 2021 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jan 24, 2019 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 31, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 6, 2018 FICS
FINAL DISPOSITION PROCESSED
Aug 6, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 24, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 24, 2018 R.PR
PUBLISHED FOR OPPOSITION
Feb 6, 2018 PUBO
NOTICE OF PUBLICATION
Jan 17, 2018 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 28, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 22, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 22, 2017 CRFA
ASSIGNED TO LIE
Dec 20, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 13, 2017 TROA
REFUSAL PROCESSED BY IB
Jul 14, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 29, 2017 RFCS
REFUSAL PROCESSED BY MPU
Jun 29, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 20, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jun 19, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Jun 17, 2017 MAFR
ASSIGNED TO EXAMINER
Jun 15, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 13, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 8, 2017 REPR